# Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-04 05:48 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Executive Summary
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs

## Intelligence Brief
Scribe Therapeutics, a biotech company focused on cardiovascular diseases, has filed for a $75 million IPO. The company, based in Alameda, uses gene-editing technology to fight cholesterol.


Coverage from Renaissance Capital, The Business Journals, Investing.com, Moomoo, and Endpoints News highlights Scribe Therapeutics' stockholder list, which includes Eli Lilly. The IPO will be listed on Nasdaq, but coverage does not yet specify when it will take place or how the public will respond.

## Verified Facts & Key Claims
### What is Scribe Therapeutics' focus?
Cardiovascular diseases

### How much is Scribe Therapeutics seeking in its IPO?
$75 million

### Who is a notable stockholder in Scribe Therapeutics?
Eli Lilly

## Key People, Organizations & Locations
IPO, Scribe Therapeutics, SCTX IPO News, Cardiovascular, Alameda, Nasdaq IPO By Investing.com, Scribe Therapeutics Stockholders Include Eli Lilly

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| renaissancecapital.com | SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO | 2026-07-02 22:20 | [Source Link](https://news.google.com/rss/articles/CBMizgFBVV95cUxQT21LYmJ6SmVzS0hXOFNhbmtiXzRWNkM4bDgwSnBxbXhVSE1pdWJZQ0RNam9nb3NsUjE5d0FmbWhqWHR2ZUJIdWVNOVpXOUVMRjhRblgxRkF5anRPUFFpcURUNHNqY2cwMWhOVzFjMjh0RmpLWWh1WmhHTlNNN2ROWG8tYVlqaHlKWjVKalo3bnhmSmFTUHc4M1l5UWZyNU1LOHBoM0p5NXdBZDE1dGdrY0RJWERtWi1kdmtUeDd1TUVyT1JNeTllY2FVRFQ3UQ?oc=5) |
| The Business Journals | Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches | 2026-07-02 22:20 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxNN3RCZGxNZHo3T3lLVC1VZl8wT1JfZU96NXhvcnVleHEweWswaEYzalZJTlZpVmxHX3ItSDQ1dG9vS251ejVMWmNZam1hZkUyMkwxSFg1V0NnMlJFRTFoMHc0VTVsaHVlTE1nMkI5MkJXRnVucUxnajJiOUhtdTc4RkFoaXk3dGJhXzZPcUd3Tks3RnczM2RvS05hUGYyQXNKR1J3YXpHOU9idDNx?oc=5) |
| Investing.com South Africa | Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com | 2026-07-02 22:20 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxQQU1hNUhNU3dqNXFUMm9vSzdRaFRoTF9jUUtuOUZpbVF3NTJSTHJGSHh4Y19VN1U2NHRIcVRKUElPalBPaEMzOHdSNTl3NWI4ZHdfNWkwcElCcVNrV29wZmJqcEZuamI2aWVhOFNBWHpNZkpEYzR2czNWS2FqcXJReHFjU1JibWNUcVA3TC1CZG4zUU5YcHZTNFpEa0lTaWwwLTdwZXREbzJYLUtvQ1NibA?oc=5) |
| Moomoo | Scribe Therapeutics Stockholders Include Eli Lilly | 2026-07-02 22:20 | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxQSzUzLVRlaW5UbF9lVUJOU1lNMG50VjBteGdIZmRRelV2MlhRWkJXdEZyVmtmNHlzcnE2bkdIRktOMGRuc1JWZ2NTTWtxMzM3RlF1Qk93X0Rhb2N3ZldseFpCTHg2QXlENEwybkVYQkVaTVQ5NDgxczg4dWZqc1d1bGI5LUlyZW9oOFBVZk85RUl4ekE1NG8w?oc=5) |
| Endpoints News | Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs | 2026-07-02 22:20 | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxORlc0RVh3NmFfSW9mbERwalZ6WHV1MkpmdW5uV0ctem5Cb3R3Rk5ESFN5UDlaMW02eC1FTEJNQk00NHpGTDVMVmRYR1hBdFJoSmtZbElEbk5sUHptZF9zaFFFR2N4UUp2c0hpb0pYbXA4LWNBUzc1b3JkRkNtQzNvaFVPd1BnT0dHZFQwSFBTZHlOc1dXSzJ6bHJFMzdpb19WZWxjRw?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-04/scribe-therapeutics-files-for-ipo-in-test-of-public-appetite-for-earlier-stage*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*